Currently Staphylococcus aureus is the predominant pathogen isolated from the respiratory tract of patients with recurrent tonsillitis. Because of an increase in multi-drug resistant strains of S. aureus, there is a pressing need for effective treatments and preventive approaches to reduce the risk of invasive and life-threatening infections. A preventive vaccine against S. aureus would have a tremendous clinical impact. However, multiple clinical trials have failed to identify an agent that can induce protective responses. Most trials have been based on subunit vaccines using one or a few purified antigens, which may not be enough to confer protection. Here, the impact of a whole-cell vaccine comprised of heat-inactivated S. aureus was investigated in patients with RT. The vaccine was well tolerated and had no significant local or systemic reactions. Immunization with heat-inactivated S. aureus elicited a significant antibody response characterized by production of IgG1 and IgG2 antibodies and, to a lesser extent, of IgA antibodies. Notably, this response was associated with an important decrease in the incidence of tonsillitis and bacterial colonization of the oropharyngeal mucosa. Our results show that whole-cell inactivated S. aureus is safe and capable of evoking specific antibody responses in patients with recurrent tonsillitis.
BackgroundUrticaria is a skin disease characterized by rapid emergence of hives, accompanied or not with angioedema. Usually lasts less than 24 hours. Approximately 12 to 24 per cent of the population will have hives or angioedema at least once in their life. Some patients with chronic urticaria has been classified as autoimmune. The autologous serum skin test (ASST) has been used to show pro-inflammatory circulating endogenous factors and it is regarded as a test for autorreactividad. The autorreactividad does not define an autoimmune urticaria, but may be an indicator of the presence of auto- reactive antibodies with the capacity of to activate the mast cells however functional antibodies need to be confirmed through of release of basophils histamine test from basophils (BHRA) and its specificity immunoassay (Western Blot or ELISA)-confirmed. Objective: to evaluate the auto-reactivity by autologous serum skin test in patients with chronic urticaria idiopathic in a study of 8 years. Material and methods: we made 216 ASST and autologous plasma skin test (APST) in patients with chronic urticaria without specific cause identified, of any age, during the period of 2003 to 2011.ResultsThirty five thousand patients were evaluated only 261 patients not identified the cause (0.6%) and we realized ASST, of these 190 (88%) were negative, and 26 (12%) were positive, 20 (76.9 %) were female and 6 (23.1%) male, the median of age for women was 30 years ago with medium of 28 and men average 29 years and median 20. Of the 26 patients one was positive for anti-thyroglobulin senior titles (1: 170) .dos with positive anti unclears and one with pANCA and cANCA positive of a total of 216 patients, 156 (72.2) had APST and 60 (27.8%) were positive, 46 (76.6%) women and 14 (23.3 %) men. Mc Neman concordance between tests P < 0.0001 and Kappa index gives us a highly significant concordance P < 0.0001. The correlation between ASST and APST by Sperman was high significance value of P < 0.001. The correlation of both tests was moderately high (76.8%).
BackgroundAllergic diseases affect 20% of world population and allergic rhinitis (AR) is the most common, alone or associated with asthma. Antigen-specific immunotherapy has been world-desensitizing type studied showing that it is capable of modifying the natural history of the disease through changes in the immune response increasing the role of clones of lymphocytes T helper type I (LTh1) and inhibiting the activity of type 2 (LTh2). Dialyzable leukocyte extract or transfer factor (TF) has shown the same stimulatory effect.ObjectiveEvaluate the synergistic effect of TF associated with SLIT in patients with RA.Material and MethodsWe studied 94 patients with RA. We included randomized into 2 groups (47 each one) both received antigen-specific sublingual immunotherapy (SLITAE) and also in group 1 was given oral TF Unit at one 200 mg monthly for 3 months, and group 2 placebo. We used a control group only to compared the normal results. All patients underwent complete blood count (BHC), immunoglobulins, quantification of cell-type lymphocyte CD3, CD4, CD8, interleukin (IL2, IL4, IL5, IL10, TNF and IFN). The nasal symptoms were evaluated monthly for 3 months, with test score symptoms questionary 4 (TSSQ4) and auto-evaluation by scale Linker.ResultsWe studied 94 AR patients (50% women and 50% men, range age between 5 and 40 years). Indoor antigens (mites, house dust and cockroach) were the main cause of allergy. Allergic patients had more eosinophiles and IgE than the healthy controls (P < 0.05). The number of CD8+ lymphocytes was slightly reduced in group 2 after treatment (P < 0.05), whereas the amount of IL-4 and IFN ƒnwere increased in both groups (P < 0.005) and the amount of IL-10 was significantly increased in group 1 (P < 0.01) after treatment. Clinical evaluation was with initial TSSQ4 of 11.6 before handling and 5.1 (44%) after, with significant improvement (P < 0.0001) and Likert score was reduced 69% than the star the treatment.ConclusionsThe TF along with SLITAE in the treatment of patients with RA did not alter the clinical improvement induced by SLITAE alone for 3 months of treatment, but the combination increased production of IL 10 and production of IFNg.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.